Clinical Trials Browser

Phase 2/3 × Stomach Neoplasms × 30 days × Clear all

NCT07221149 2026-03-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Phase 2/3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms